2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2015
Body Mass Index Genetic Risk Score and Endometrial Cancer Risk
Prescott J, Setiawan VW, Wentzensen N, Schumacher F, Yu H, Delahanty R, Bernstein L, Chanock SJ, Chen C, Cook LS, Friedenreich C, Garcia-Closas M, Haiman CA, Le Marchand L, Liang X, Lissowska J, Lu L, Magliocco AM, Olson SH, Risch HA, Shu XO, Ursin G, Yang HP, Kraft P, De Vivo I. Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLOS ONE 2015, 10: e0143256. PMID: 26606540, PMCID: PMC4659592, DOI: 10.1371/journal.pone.0143256.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskBody mass indexGenotype risk scoreCancer riskRisk scoreHigher body mass indexRisk allelesIndependent risk factorEndometrial cancer casesExcess body weightRisk factor dataGenetic risk scoreGenome-wide association studiesEndometrial cancerMass indexBMI riskRisk factorsEffect modificationCancer casesRisk lociBody weightCancer shareExploratory analysisStudy designControl participants
2014
Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia
Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, Yang H, Chanock S, Brinton L, Hartge P, Lissowska J, Park SL, Cheng I, Bush WS, Crawford DC, Ursin G, Horn-Ross P, Bernstein L, Lu L, Risch H, Yu H, Sakoda LC, Doherty J, Chen C, Jackson R, Yasmeen S, Cote M, Kocarnik JM, Peters U, Kraft P, De Vivo I, Haiman CA, Kooperberg C, Le Marchand L. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 2014, 35: 2068-2073. PMID: 24832084, PMCID: PMC4146418, DOI: 10.1093/carcin/bgu107.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskSingle nucleotide polymorphismsEndometrial Cancer ConsortiumEndometrial cancer casesBody mass indexProstate cancer riskMultiple cancer sitesEvidence of heterogeneityMass indexCancer sitesProstate cancerBonferroni-corrected P valueCancer casesCancer-associated single nucleotide polymorphismsCancer ConsortiumGenome-wide association studiesCancerStatistical significanceP-valueEpidemiologyRiskBiological mechanismsEuropean ancestry
2013
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factorsPolymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk
Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO. Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 216-223. PMID: 23221126, PMCID: PMC3677562, DOI: 10.1158/1055-9965.epi-12-0903.Peer-Reviewed Original ResearchMeSH KeywordsAsian PeopleBiomarkers, TumorCase-Control StudiesChinaEndometrial NeoplasmsFemaleFollow-Up StudiesGene Expression ProfilingGenetic Predisposition to DiseaseHumansInflammationLinkage DisequilibriumMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotidePrognosisRisk FactorsConceptsEndometrial cancer riskEndometrial cancer casesEndometrial cancerSingle nucleotide polymorphismsOdds ratioCancer casesEndometrial carcinogenesisCancer riskStage IConfidence intervalsInflammation pathway genesInflammatory pathway genesAllelic odds ratioChronic inflammationEpidemiologic evidenceInflammatory pathwaysPathway genesSignificant associationStage IIGenetic susceptibilityMMP9 polymorphismsAdditional studiesCancerGenetic polymorphismsFollow-up genotyping